CRISPR-based gene therapy targeting diabetic retinopathy, using liposome delivery to achieve spatial–temporal release of CRISPR agents to affected retinal cells. Therapeutic value proposition: halt or reverse disease progression by correcting disease-associated genetic dysfunction.